Ctrl Worx Watch List › Company

BioForce Nanosciences Holdings, Inc. (BFNH): material weakness open at least 2,128 days

By , Ctrl Worx™. Built from its own SEC filings. How the Clock works.

BioForce Nanosciences Holdings, Inc. stated in 23 SEC filings since Feb 16, 2021 that it has one or more material weaknesses in its internal control over financial reporting. The filings gave no conclusion on whether that control is effective. The latest was its 10-Q for the period ended Jun 30, 2026.

Ctrl Worx Watch List™ status

On the Clock
5.8 yearsopen since at least Dec 31, 2020
10-Q, Aug 10, 2026latest filing that reports the weakness. Read it on SEC EDGAR
#60 of 1,250on the Clock by time open, tied with 236 other companies that share its start date. See the Clock

Still filing, and no annual report of its own says the weakness is fixed.

Checked against SEC EDGAR: Oct 29, 2026 · Entry #10512

Filings with a weakness23
First in our dataFeb 16, 2021
AuditorMICHAEL GILLESPIE & ASSOCIATES, PLLC

Causes the company named

Segregation of duties · 23Financial close and reporting · 21

What the latest filing says

Officer and Principal Financial Officer, after considering the existence of material weaknesses identified, determined that our internal control over financial reporting disclosure controls and procedures were not effective as of June 30, 2026. Evaluation of Internal Control over Financial Reporting Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934, as amended. Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles. Our internal control over financial reporting includes those policies and procedures that: (i) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets, (ii) provide reasonable assurance that transactions are recorded as necessary [...]

From the controls section of the 10-Q filed Aug 10, 2026. Read the full filing on SEC EDGAR.

Company response: BioForce Nanosciences Holdings, Inc. can send a statement or a link to its remediation update to russell@ctrlworx.com. We post it here, unedited and dated.

Filings

FiledFormPeriodControlsCausesFiling
Aug 10, 202610-QJun 30, 2026Material weakness stated, no ICFR conclusionSegregation of duties; Financial close and reportingEDGAR
May 19, 202610-QMar 31, 2026Material weakness stated, no ICFR conclusionSegregation of duties; Financial close and reportingEDGAR
Apr 15, 202610-KDec 31, 2025Material weakness stated, no ICFR conclusionSegregation of duties; Financial close and reportingEDGAR
Nov 19, 202510-QSep 30, 2025Material weakness stated, no ICFR conclusionSegregation of duties; Financial close and reportingEDGAR
Aug 11, 202510-QJun 30, 2025Material weakness stated, no ICFR conclusionSegregation of duties; Financial close and reportingEDGAR
May 13, 202510-QMar 31, 2025Material weakness stated, no ICFR conclusionSegregation of duties; Financial close and reportingEDGAR
Apr 8, 202510-KDec 31, 2024Material weakness stated, no ICFR conclusionSegregation of duties; Financial close and reportingEDGAR
Nov 8, 202410-QSep 30, 2024Material weakness stated, no ICFR conclusionSegregation of duties; Financial close and reportingEDGAR
Aug 7, 202410-QJun 30, 2024Material weakness stated, no ICFR conclusionSegregation of duties; Financial close and reportingEDGAR
May 3, 202410-QMar 31, 2024Material weakness stated, no ICFR conclusionSegregation of duties; Financial close and reportingEDGAR
Apr 1, 202410-KDec 31, 2023Material weakness stated, no ICFR conclusionSegregation of duties; Financial close and reportingEDGAR
Nov 3, 202310-QSep 30, 2023Material weakness stated, no ICFR conclusionSegregation of duties; Financial close and reportingEDGAR
Aug 1, 202310-QJun 30, 2023Material weakness stated, no ICFR conclusionSegregation of duties; Financial close and reportingEDGAR
May 9, 202310-QMar 31, 2023Material weakness stated, no ICFR conclusionSegregation of duties; Financial close and reportingEDGAR
Mar 28, 202310-KDec 31, 2022Material weakness stated, no ICFR conclusionSegregation of duties; Financial close and reportingEDGAR
Nov 2, 202210-QSep 30, 2022Material weakness stated, no ICFR conclusionSegregation of duties; Financial close and reportingEDGAR
Jul 27, 202210-QJun 30, 2022Material weakness stated, no ICFR conclusionSegregation of duties; Financial close and reportingEDGAR
May 5, 202210-QMar 31, 2022Material weakness stated, no ICFR conclusionSegregation of duties; Financial close and reportingEDGAR
May 5, 202210-Q/AMar 31, 2022Material weakness stated, no ICFR conclusionSegregation of duties; Financial close and reportingEDGAR
Feb 11, 202210-KDec 31, 2021Material weakness stated, no ICFR conclusionSegregation of duties; Financial close and reportingEDGAR
Jul 30, 202110-Q/AJun 30, 2021Material weakness stated, no ICFR conclusionSegregation of dutiesEDGAR
Apr 27, 202110-QMar 31, 2021Material weakness stated, no ICFR conclusionSegregation of dutiesEDGAR
Feb 16, 202110-KDec 31, 2020Material weakness stated, no ICFR conclusionSegregation of duties; Financial close and reportingEDGAR

Others on the Clock in the same industry

By SEC industry code: 3826, Laboratory Analytical Instruments, then related codes.

Follow BFNH for free

Get an email when BioForce Nanosciences Holdings, Inc files a 10-K or 10-Q that reports a material weakness, or says its controls are effective again.

Want the next one the day it's filed?

MW Pro sends an alert the day a company you follow reports a material weakness or says it fixed one. Founding price $990 a year.

Join the MW Pro waitlistLook up any company in Controls Radar™

Watch List Weekly: new material weaknesses, fixes and the longest-running cases, every Monday.

One email to confirm, then one email each Monday. Every email has a one-click unsubscribe. Privacy policy

Based on public SEC filings. Causes are grouped into standard categories by Ctrl Worx. The filings are the authority. Ctrl Worx is not affiliated with BioForce Nanosciences Holdings, Inc. or the SEC. Not investment advice. Why you can rely on the Watch List.